Abstract P2-16-04: A phase 2 study of ridaforolimus (RIDA) and dalotuzumab (DALO) in estrogen receptor positive (ER+) breast cancer

José Baselga, HS Rugo, Ahmad Awada et al.|Cancer Research|2013

Cited by 3